Status:

WITHDRAWN

A Study to Evaluate the Safety and Effectiveness of TRIGEN™ INTERTAN™ (10S Models)

Lead Sponsor:

Smith & Nephew Medical (Shanghai) Ltd

Conditions:

Femoral Fractures

Hip Fractures

Eligibility:

All Genders

18+ years

Brief Summary

This is a post-market study to evaluate the revision rate of femoral fractures, treated with INTERTAN 10S Nails at one-year post-operation. The study will enroll Approximately 180 subjects with femora...

Detailed Description

Background: The INTERTAN nail was designed to improve upon existing intramedullary nail systems. INTERTAN nails utilize two interlocking screws, thereby improving controlled intertochanteric fracture...

Eligibility Criteria

Inclusion

  • Subjects who sign the informed consent form (ICF) voluntarily.
  • Subjects who have a femoral fracture and are scheduled for repair using an INTERTAN 10S Nail.
  • Male or female subjects aged 18 years or older, with mature bone development at time of implantation.
  • Subjects who agree to follow all study visits and procedures.

Exclusion

  • Subjects with known hypersensitivity to the device or implant materials.
  • Subjects in which use of the device would cross open epiphyseal plate(s).
  • Subjects with complex intertrochanteric and femoral neck fractures.
  • Subjects with an existing condition that predisposes them to a poor outcome, such as blood supply limitations, insufficient bone quality or quantity, obliterated medullary canal, previous infections or other conditions which tend to retard healing.
  • Subjects not suitable for operation due to obvious local or systemic infection.
  • Subjects who are unable to tolerate anesthesia and surgery due to cardiopulmonary failure or other serious diseases.
  • Subjects with a congenital or acquired bony deformity.
  • Subjects with Body Mass Index (BMI) of ≥ 35.
  • Subjects with hypovolemia, hypothermia, or coagulopathy.
  • Subject is immunosuppressed, has an autoimmune disorder or an immunosuppressive disorder. For examples, subjects are on immunosuppressive therapy (cortisol at large dose, cytotoxic drugs, antilymphocytic serum or irradiation at large doses) or has acquired immunodeficiency syndrome (AIDS).
  • Subjects with any existing hardware that would preclude the use of the nail.
  • Subjects with mental or emotional conditions or any other clinical conditions that, in the opinion of the Investigator, would preclude cooperation and compliance with the rehabilitation regimen.
  • Subjects with medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
  • Subject is a woman who is pregnant or lactating, or intends to become pregnant during the course of the study follow-up.
  • Subjects who have participated in any other clinical trial within 3 months of Screening.
  • Subjects who have participated previously in this clinical study and were withdrawn for any reason.

Key Trial Info

Start Date :

June 23 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 1 2025

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04865146

Start Date

June 23 2022

End Date

January 1 2025

Last Update

February 7 2024

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

The Second Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China, 230601

2

The Third Hospital of Hebei Medical University

Shijiazhuang, Hebei, China, 050051

3

Tang Shan 2rd Hospital

Tangshan, Hebei, China, 063000

4

The First Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, China, 116011